Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies

24 Jun 2023

Abstract excerpt

The human complement system plays a crucial role in immune defense. However, its erroneous activation contributes to many serious inflammatory diseases. Since most unwanted complement effector functions result from C5 cleavage into C5a and C5b, development of C5 inhibitors, such as clinically approved monoclonal antibody eculizumab, are of great interest. Here, we developed and characterized two anti-C5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Blood groups and transfusion
Share to Complement system in diseases
Share to Monoclonal and Polyclonal Antibodies Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37356719
DOI: 10.1016/j.jbc.2023.104956

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesPMID 37356719Read ↗

Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodiesSemantic proximity Read ↗

Structure, function and control of complement C5 and its proteolytic fragments.Semantic proximity Read ↗

Multifaceted Activities of Seven Nanobodies against Complement C4bSemantic proximity Read ↗

Protein therapeutics and their lessons: Expect the unexpected when inhibiting the multi‐protein cascade of the complement systemSemantic proximity Read ↗

Structural Basis for Eculizumab-Mediated Inhibition of the Complement Terminal Pathway.Semantic proximity Read ↗

Rational Engineering of a Minimized Immune Inhibitor with Unique Triple-Targeting PropertiesSemantic proximity Read ↗

Structural modelling of human complement FHR1 and two of its synthetic derivatives provides insight into their <i>in-vivo</i> functionsSemantic proximity Read ↗

Eculizumab treatment efficiently prevents C5 cleavage without C5a generation in vivoSemantic proximity Read ↗

Complement is activated by elevated IgG3 hexameric platforms and deposits C4b onto distinct antibody domainsSemantic proximity Read ↗

Structural evaluation of a nanobody targeting complement receptor Vsig4 and its cross reactivitySemantic proximity Read ↗

Stratification of responders towards eculizumab using a structural epitope mapping strategy.Semantic proximity Read ↗

A synthetic protein as efficient multitarget regulator against complement over-activationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.